IMPACT Study

  • Research type

    Research Study

  • Full title

    Evaluation of safety and efficacy of a resorbable collagen IMplant in treatment of High Grade PArtial ThiCkness Tears; A prospective, multicenter, randomized, control trial (IMPACT Study).

  • IRAS ID

    313910

  • Contact name

    Ali Narvani

  • Contact email

    Ali.Narvani@nhs.net

  • Sponsor organisation

    Smith + Nephew, Inc.

  • Clinicaltrials.gov Identifier

    NCT05444465

  • Duration of Study in the UK

    2 years, 8 months, 1 days

  • Research summary

    The rotator cuff is a group of muscles and their tendons that act to hold the shoulder in place. Torn rotator cuff tendons are common injuries that result in shoulder weakness and pain. These injuries can be treated with medications, injections, and physical therapy. However, when symptoms continue despite these treatments, surgery is often recommended to repair the injured tendon.
    One option for repairing torn rotator cuff tendons involves applying a protective layer of collagen over the injured tendons to aid in healing and stop disease progression. Collagen is the most commonly found protein in the body and is present in the skin, bones, tendons and ligaments. The REGENETEN™ Bioinductive Implant, which has been approved to be used in patients and is commercially available on the market (CE marked), is put in the shoulder during surgery to provide a layer of collagen over injured tendons.
    The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique ‘Completion and Repair’ for surgically treating partial-thickness rotator cuff tears. Several doctors at up to 25 sites globally will be collecting study data from 156 patients. All patients will be assigned randomly either to be treated with REGENETEN™ or standard surgical repair without the use of REGENETEN™. The treatment received will be blinded to the patient and they will be told which treatment they received when they finish in the study. Patient participation will last for about 2 years.

  • REC name

    West Midlands - South Birmingham Research Ethics Committee

  • REC reference

    22/WM/0147

  • Date of REC Opinion

    26 Jul 2022

  • REC opinion

    Further Information Favourable Opinion